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Hypoxia is a key driver of tumor adaptation promoting tumor progression and resistance
to therapy. Hypoxia related pathways might represent attractive targets for the treatment
of Glioblastoma Multiforme (GBM), that up to date is characterized by a poor prognosis.
Primary aim of this study was to investigate the role of hypoxia and hypoxia-related
modifications in the effect of temozolomide (TMZ) given alone or in association with
the antidiabetic agent Metformin (MET) or the PI3K/mTOR blocker, BEZ235. The study
was conducted in the TMZ responsive U251 and resistant T98 GBM cells. Our results
showed that during hypoxia, TMZ plus MET reduced viability of U251 cells affecting
also CD133 and CD90 expressing cells. This effect was associated with a reduction of
HIF-1α activity, VEGF release and AKT activation. In T98 TMZ-resistant cells, TMZ plus
MET exerted similar effects on HIF-1α. However, in this cell line, TMZ plus MET failed to
reduce CD133 positive cells and AKT phosphorylation. Nevertheless, the administration
of the dual PI3K/mTOR inhibitor BEZ235 potentiated the effect of TMZ plus MET on
cell viability, inducing a pro-apoptotic phenotype during hypoxic condition also in T98
cells, suggesting the block of the PI3K/AKT/mTOR pathway as a complementary target
to further overcome GBM resistance during hypoxia. In conclusion, we proposed TMZ
plus MET as suitable treatment to revert TMZ-resistance also during hypoxia, an effect
potentiated by the inhibition of PI3K/mTOR axis.
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INTRODUCTION
In Glioblastoma Multiforme (GBM), the “international gold standard” therapy includes surgery,
radiotherapy, and chemotherapy with Temozolomide (TMZ) (1), but the prognosis remains poor.
The glycolytic switch and hypoxia-induced factors influence tumor progression and resistance to
therapy (2, 3). Indeed, hypoxia and hypoxia-related factors are associated with pseudopalisading
necrotic regions that protect stem cells niche, contributing to the aggressive profile of these tumors
(3, 4). Hypoxia effect on tumor malignancy involves hypoxia-inducible factors (5), stem population
(6), negative modulation of apoptotic axis (7) and molecular pathways related to regulation of cell
metabolism including PI3K/AKT/mTOR pathway (8).
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Metformin (MET), a modulator of cell metabolism acting on
5′ adenosine monophosphate-activated protein kinase (AMPK)
and mitochondrial respiration, potentiates the activity of TMZ
in glioblastoma models (9, 10). Despite the various hypothesis
suggested including ours (11–13), the precise mechanism of
action of MET remains elusive particularly regarding its activity
under hypoxic condition.
As previously stated, hypoxia influences metabolic
pathway related to the control of cell metabolism including
PI3K/AKT/mTOR favoring tumor proliferation and resistance
(14). However, PI3K/AKT signaling is activated by loss of
function mutations or reductions of mitochondrial PTEN (15), a
molecular feature common in GBM (more than 40%). For this
reason, in presence of activating mutations, PI3K/AKT/mTOR
pathway influences GBM cell growth also during normoxic
conditions. Indeed, administration of the dual PI3K and mTOR
inhibitor, BEZ235, is able to reduce GBM chemoresistance,
leading G1 cell cycle arrest and downregulation of vascular
endothelial growth factor (VEGF) (16–18).
For the reasons above, in this study we initially investigated
the role of hypoxia and hypoxia-related modifications on the
effect of Temozolomide given alone or in association with drug
targeting cell metabolism such as Metformin.
In detail, we tested the role of hypoxia on the add-on effect of
MET on TMZ (COMBO), on cell viability, HIF-1α activity, AKT
phosphorylation and VEGF release. The study was conducted in
two different GBM cell lines, i.e., the TMZ-responsive U251 and
the -resistant T98, both carrying mutation in PTEN, previously
evaluated under normoxic condition. Subsequently, in order to
test the specific role of PI3K/AKT/mTOR pathway, the effect of
COMBO was evaluated also in presence of the dual PI3K/mTOR
inhibitor BEZ235.
MATERIALS AND METHODS
Cell Culture and Reagents
U251-HRE and T98 human glioma cells (both TP53 and PTEN
mutated) were routinely maintained in RPMI supplemented
with 10% heat-inactivated fetal bovine serum, penicillin, and
streptomycin (50 IU/ml), 2mM glutamine (Euroclone, UK),
25mMHepes Buffer. Cells have been maintained in a humidified
atmosphere of 5% of CO2 at 37
◦C. To perform hypoxia
experiments, both cell lines were seeded at 10,000 cells/cm2
and incubated in a “Hypoxic Chamber” containing 1% O2 gas
mixture with or without 25µM TMZ (dissolved in 90% PBS
and 10% Dimethyl sulfoxide, DMSO), 10mMMET (dissolved in
100% PBS) (both Sigma- Aldrich, St. Louis, MO, USA) for 24,
48, and 72 h for cell viability and for 48 h for all other tests and
1µMBEZ235 (dissolved in 100% DMSO) for 48 h (SelleckChem,
Houston, TX, USA). Treatment with TMZ plus Met was defined
as COMBO. Cell viability was evaluated using the Trypan blue
exclusion test.
HIF-1α Transcription Activation Assay
Nuclear extracts were prepared by using Nuclear Extract Kit
from Vincibiochem (#40010 - Activemotif, CA, USA) according
to the manufacturer’s instructions. The transcriptional activity
TABLE 1 | Primers used for Real-time PCR.
Gene Forward Reverse
β-actin TCAAGATCATTGCTCCTCCTG CCAGAGGCGTACAGGGATAG
Bax ATG GAC GGG TCC GGG GAG ATCCAGCCCAACAGCCGC
Bad CCCAGAGTTTGAGCCGAGTG CCCATCCCTTCGTCGTCCT
Bcl-2 GATTGTGGCCTTCTTTGAG CAAACTGAGCAGAGTCTTC
of HIF-1α was assayed by an ELISA-based kit [#47096-
TransAM Kit, Vinci-Biochem, Vinci (FI), Italy] according to the
manufacturer’s instructions. Nuclear extract samples were added
to the coated plate and analyzed with GloMax-Multi Detection
System (Promega,Milan, Italy). Data are expressed asHIF-1alpha
activity (ABS OD 450 nm).
The evaluation of HIF-1 target gene was performed by
measuring the concentration of VEGF in glioma cell-conditioned
medium quantified using an ELISA kit (VEGF Human ELISA
KitNovex R©, Cat. No. KHG011, Life Technologies, Monza, Italy)
in accordance with themanufacturer’s protocol. Themediumwas
collected under normoxic and hypoxic conditions. The data are
expressed in pg/mL.
RNA Extraction and Real-Time PCR
RNA was extracted using the commercially available
illustraRNAspin Mini Isolation Kit (GE Healthcare, Italy),
according to manufacturer’s instructions. Total RNA was
reverse-transcribed to cDNA using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystem, USA). Real-time
PCR was performed in duplicate for each data point, and the
oligonucleotides used were as in Table 1. Changes in the target
mRNA relative to housekeeping (β-actin) were determined with
the ddct Method.
FACS Analysis
One hundred thousand cells were washed in PBS and incubated
with 0.5 µg of: CD90-FITC, human (clone: DG3)-FITC, human
130-095-403; Monoclonal CD133/2 (293C3)-FITC, human 130-
090-853; CD44-FITC, mouse (clone: IM7.8.1) 130-102-511;
CD73-PE, human (clone: AD2)-FITC, human 130-095-182
(MiltenyiBiotec). Viable cells were gated by forward and side
scatters and analyzed on 100,000 acquired events for each sample
(PartecCyFlow Space using the PartecFloMax R© software).
Bioluminescent Assay
For cell transfection, the glioma cell lines were seeded at
10,000 cells/cm2 and transfected with pHRE-luciferase plasmid
(kindly provided by Dr. G. Melillo, National Cancer Institute,
Frederick, MD, USA) that expresses the luciferase reporter gene
under the control of three copies of the Hypoxia-Response
Element (HRE) sequence (pGL2Tk-HRE) (19). The cells were
analyzed using the GloMax-Multi Detection System (Promega,
Milan, Italy). Protein content was measured by means of a
Bradford assay, and the bioluminescence signal was normalized
to milligrams of protein and expressed as relative luminescence
units (RLU = luciferase counts per milligram of proteins).
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The cells were also tested for Caspase-3 activity by Caspase-
Glo R© Assay (Promega). Briefly, 10,000 cells/cm2 were treated, as
previously described, and the relative luminescence units at the
end of the treatment was detected using a plate reader (Glomax)
and after protein normalization, data were expressed as RLU
(Relative Luminescence units).
ELISA AKT
Ten thousand cells/cm2 were treated as previously described
and, at the end of the treatments, U251 and T98 cell pellets
were lysed for 30min. After protein quantification, lysates were
used to assess pAKT [pS473]. A monoclonal antibody specific
for AKT has been coated onto the wells of the microtiter strips
provided (AKT [pS473] Phospho-ELISA Kit, HumanCatalog
number: KHO0111 ThermoFisher). The absorbance was read at
450 nm and after plot on graph paper data were expressed as units
of pAKT/ml.
Statistical Analysis
in vitro experiments were repeated three times, giving
reproducible results. Data are presented as mean values ±
standard deviation (SD) of three independent experiments.
For statistical analysis t-test or one- or two-way analysis of
variance (ANOVA), followed by Dunnett’s or Bonferroni’s
multiple comparison tests, were performed using Prism 4
(GraphPadSoftwareInc., CA, USA).
RESULTS
COMBO Reduces the Hypoxia-Dependent
Increase of Cell Viability and HIF-1α
Activation, Also in T98 Cells
As we have previously shown in a dose-response assay (12),
25µMTMZ is the correct dose to distinguish the drug sensitivity
of U251 and T98 cell lines. Here, we evaluated the effect of 25µM
TMZ and 10mM MET in combination (COMBO) on HIF-1α
transcriptional factor in the two cell lines both in normoxia
and in hypoxia. To this aim, both cell lines were incubated for
6 h in a hypoxia chamber and then were analyzed by using an
ELISA-based assay for HIF-1 nuclear form.
In both cell lines, we observed a dramatic increase in the
transcriptional activity of HIF-1α induced by hypoxia. In U251
cells, all single and combined treatments were able to significantly
reduce HIF-1α activity, also in hypoxia (Figure 1A). Otherwise,
in T98 TMZ-resistant cells, only COMBO significantly reduced
the activity of HIF-1α compared to controls (Figure 1B).
However, in both cell lines, neither single or COMBO treatment
was able to restore HIF- 1α activity to the levels observed during
normoxia. The functional effect on HIF-1α modulation was
shown by the results obtained on VEGF, a key target gene of
HIF-1α (Figures 1C,D).
In order to evaluate the role of hypoxia on treatment effect, we
assessed cell viability in both cell lines in absence or presence of
TMZ, MET or COMBO by trypan blue exclusion test.
In U251 cells, both TMZ and COMBO significantly reduced
the number of cells starting from 24 h of treatment (Figure 1E).
Otherwise, in hypoxic condition, COMBO but not MET reduced
viability of T98 cells starting at 48 h. To observe a significant effect
of MET, 72 h needed (Figure 1F).
As regard to apoptotic genes, whereas hypoxia in U251 cells
increased both pro- and anti-apoptotic genes, TMZ and COMBO
promoted a balance between the up-regulation of pro-apoptotic
genes, particularly Bax in COMBO and the down-regulation
of the anti-apoptotic gene Bcl-2 (Figure 1G). In T98 cells,
COMBO was the only treatment able to significantly increase
pro-apoptotic genes and reduce the anti-apoptotic Bcl-2 gene
(Figure 1H). However, the net effect was similar to that exerted
by 25µM TMZ. None of the drugs modified Caspase 3 levels in
both cell lines (Supplementary Figure 1).
MET, TMZ, and COMBO Differently
Modulate Markers Associated With GBM
Malignancy During Hypoxia
To better understand the role of hypoxia on different cell markers
of malignancy, the effect of 10mM MET, 25µM TMZ and
COMBO on the relative abundance of CD133, CD90, CD44,
and CD73 positive cells was evaluated during hypoxic condition.
We previously demonstrated (12) that 10mM MET alone and
COMBO counteracted CD133 expression in U251 cells. Here,
during the hypoxic condition, we observed a dramatic increase
of CD133, CD90, and CD73. Only COMBO reduced the hypoxia-
dependent increase in CD133, CD90, and CD73. On the contrary,
when TMZ and MET were administered alone effects were
marker dependent, being the first active on both CD90 and
CD73 and the last only on CD133 (Figure 2A). Thus, COMBO
treatment is suitable to potentiate the effects observed with TMZ
treatment on all subpopulation of cells.
For what concerns T98 resistant cells, we confirmed that also
in hypoxia the mechanism to overcome resistance could not be
attributable to CD133 modulation. Contrary to what observed
for normoxia condition, where TMZ produced an enrichment of
CD90 labeled cells (12), during hypoxic condition we observed
a TMZ induced reduction of this marker (Figure 2B). Despite
the pronounced increase induced by MET, COMBO effects were
similar to those observed for TMZ (Figure 2B). For both cell
lines, we observed no or only slight effects on CD44 marker.
In addition, Real time-PCR (Supplementary Figure 2)
confirmed that CD133 production was affected only in U251 in
presence of MET, data that correlated with the CD133 expression
on the membrane. Taken together, results on cell markers
indicate that during hypoxia COMBO but not TMZ or MET
alone, reduced the increase of selected cell populations, an effect
that was not observed in T98 cells.
In T98 Cells, BEZ235 Potentiates the
Inhibitory Effect of COMBO on the
Hypoxia-Independent Activation of HIF-1α:
an Effect That Involves the
PI3K/AKT/mTOR Pathway
We previously showed that TMZ dramatically reduced HIF-
1α levels also during normoxic condition (18). Moreover, we
observed that the effect of TMZ was similar to that obtained with
BEZ235 for 48 h (18), a PI3K/AKT/mTOR modulator known to
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FIGURE 1 | HIF-1α activity modulation and consequences on the apoptotic pattern. ELISA-based HIF-1α activity quantification after 48 h of 25µM TMZ, 10mM MET,
or COMBO treatment under normoxic and hypoxic conditions in U251 (A) and T98 (B) cells. The data are expressed as absorbance at 450 nm. *p < 0.05, ***p <
0.001 vs. control under normoxic conditions; #p < 0.05, ##p < 0.001 vs. control under hypoxic conditions. The evaluation of HIF-1 target gene, VEGF, was
performed by the ELISA of the VEGF released by U251 (C) and T98 (D) glioma cells in cell medium after 25µM TMZ, 10mM MET or COMBO treatment. *p < 0.05,
***p < 0.001 vs. control under normoxic conditions; #p < 0.05, ##p < 0.001 vs. control under hypoxic conditions. Evaluation of time-response viability of responsive
and resistant cells after TMZ or COMBO. Cell viability was assessed by means of a Trypan blue exclusion test and expressed as the percentage of viable cells after 24,
(Continued)
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FIGURE 1 | 48, or 72 h of treatment under hypoxic condition in U251 (E) and T98 (F) cells. **p < 0.01; ***p < 0.001 vs. control cells. The induction of pro-apoptotic
(Bad and Bax) and anti-apoptotic genes (Bcl-2) was analyzed by means of real-time PCR in glioma cells treated with TMZ under hypoxic condition (G,H). The data
were normalized to β-actin, and the 11ct values were expressed as the ratio between the mean values in the responsive and resistant cells [Fold of Induction (FOI)].
*p < 0.05; ***p < 0.001 treated vs. control cells. Mean values ± SD of three independent experiments.
FIGURE 2 | Modulation of key markers of malignancy after treatment. FACS
analysis for CD133, CD90, CD44, and CD73 markers in U251 (A) and T98 (B)
cells after 48 h of treatment with 25µM TMZ and/or of 10mM MET under
hypoxia. Data were expressed as the percentage of positive cells on the
number of total cells. Data are shown as the mean ± standard deviation. *p <
0.05; **p < 0.01; ***p < 0.001 vs. control sample (in normoxia).
regulate HIF-1α levels in a hypoxic independent manner. In this
work, we further investigated the effect of 25µM TMZ given
alone or in combination with 10mM MET on the hypoxia-
independent activation of HIF-1α levels in both responsive
U251 and resistant T98 cells. Furthermore, in order to better
understand the role of AKT modulation on HIF-1α regulation
and treatment efficacy, drug’s effects were compared with those
of 1µM BEZ235, given alone or in association with TMZ, MET
or COMBO for 48 h. To this aim, a powerful strategy based on
a luciferase reporter tool under the control of HRE sequences
was used.
In U251 cells, MET, TMZ, or COMBO significantly down-
regulated HIF-1α (Figure 3A). In these cells, MET, COMBO, or
BEZ235 reduced HIF-1α activity, more than TMZ (Figure 3A).
No add-on effect was observed when BEZ235 was associated with
MET and COMBO.
In T98 cells, TMZ given alone increased HIF-1α activity.
On the contrary, the association with MET reverted this effect
producing a reduction of HIF-1α activity (Figure 3B). In these
cells, the highest effect on HIF-1α activity was obtained when
MET was associated with BEZ235 alone or plus TMZ. BEZ235
given alone or in association with TMZ reduced HIF-1α activity
but to a lower extent (Figure 3B).
In order to understand if the modification on HIF-1α
activity was associated with alterations in AKT activation
and/or oxygenation state, we assessed the effect of TMZ, MET,
and COMBO on AKT phosphorylation, during normoxic and
hypoxic conditions. In the same experimental task, the effect of
BEZ235 given alone or in combination was also evaluated.
Cell oxygenation state only minimally influenced drug effects
on AKT phosphorylation. BEZ235 given alone or in association
produced the highest inhibition of AKT phosphorylation in both
cell lines (Figure 4). MET or COMBO reduced AKT activation
only in U251 but the reduction observed was lower than the
one exerted by BEZ235 alone (Figures 4A,B). Finally, no effect
on AKT activation was observed with TMZ (Figures 4A–D).
These results confirm that BEZ235 effect on AKT activation
is independent on hypoxia and that COMBO modulates AKT
activity only in U251 cells.
Block of PI3K/AKT/mTOR Axis Potentiates
the Effect of COMBO Particularly During
Hypoxic Condition
After, we investigated the role of the PI3K/AKT/mTOR
pathway on cell viability and apoptotic profile during
normoxic and hypoxic conditions. We previously showed
that hypoxia reduced the effect of 10mM MET in T98
cells but not that of COMBO (Figure 1). In both cell
lines, after 48 h treatment, 1µM BEZ235 increased the
effect of COMBO independently from the oxygenation
state. BEZ235 alone reduced the viability of U251 but
not that of T98 cells and only during hypoxic conditions
(Figures 5A,B), suggesting that the block of AKT
phosphorylation is not sufficient to reduce cell viability
during the normoxic condition.
Finally, we evaluated the effect of 1µM BEZ235 on apoptotic
genes in normoxia and hypoxia. In U251 cells, BEZ235 in
association with MET or COMBO promoted pro-apoptotic
genes (Bax, Bad) with a significant down-regulation of anti-
apoptotic Bcl-2 gene, also in hypoxic condition (Figure 5C).
BEZ235 alone produced only a slight reduction in Bcl-2
during normoxia indicating that BEZ requires a reduction
of oxygen to modify Bcl-2 levels. In T98 cells, BEZ235
associated with TMZ, MET or COMBO reverted the hypoxic
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FIGURE 3 | BEZ235 effect on HIF-1α activity modulation. HIF-dependent luciferase activity was analyzed in cell lysates and expressed as the percentage variation in
Relative Luminescence Units (RLUs) in U251 TMZ-responsive (A) and T98 TMZ-resistant cells (B) after 25µM TMZ, 10mM MET, COMBO and/or 1µM BEZ235 in
combination with all the drugs for 48 h. *p < 0.05; **p < 0.01; ***p < 0.001 vs. control cells.
FIGURE 4 | pAKT modulation by single and combined treatments. pAKT (Ser473) levels were assessed by mean ELISA assay and expressed as units/ml in normoxia
(A,C) and hypoxia (B,D) in U251 (A,B) and T98 (C,D) cells after 25µM TMZ, 10mM MET, COMBO and/or 1µM BEZ235 in combination with all the drugs for 48 h. *p
< 0.05; **p < 0.01; ***p < 0.001 treated vs. control cells. Mean values ± SD of three independent experiments.
profile restoring a “sensitive-like” pattern of apoptotic genes
(Figure 5D) reaching levels higher than those observed after
COMBO or TMZ alone (Figure 1H). Again, in agreement
with the results obtained from cell viability, this effect was
not observed when BEZ235 was given alone. Taken together
these results indicate that targeting PI3K/AKT/mTOR pathway
increases cell mortality during hypoxia condition also in
the TMZ-resistant cell model, but only when associated
with COMBO as confirmed also by the increased Caspase-
3 activation in COMBO plus BEZ235- treated samples
(Supplementary Figure 1). However, particularly during
normoxia, the effect of BEZ235 alone is not sufficient to modify
tumor cell viability.
DISCUSSION
In this work, first we investigated the effect of MET as a TMZ-
adjuvant agent in hypoxia in GBM cell lines. In our previous
paper, MET showed significant efficacy in the overcoming TMZ-
resistance in a glioma model both in vitro during normoxic
conditions and in vivo (12).
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FIGURE 5 | BEZ235 supports COMBO in the modulation of cell viability. Cell viability of responsive and resistant cells after 25µM TMZ, 10mM MET, COMBO and/or
1µM BEZ235 in combination with all the drugs. Cell viability was assessed by means of a Trypan blue exclusion test and expressed as the percentage of viable cells
after 48 h of treatment under normoxic or hypoxic conditions in U251 (A) and T98 (B) cells. *p < 0.05; **p < 0.01; ***p < 0.001 vs. control cells (i.e., untreated cells.
For normoxia, control cells are represented by untreated cells in normoxia and the same normalization was used for experiments in hypoxia). The induction of
pro-apoptotic (Bad and Bax) and anti-apoptotic genes (Bcl-2) was analyzed by means of real-time PCR in glioma cells treated with 25µM TMZ, 10mM MET, COMBO
and/or 1µM BEZ235 in combination with all the drugs for 48 h under normoxic or hypoxic conditions in U251 (C) and T98 (D) cells. The data were normalized to
β-actin and the 11ct values were expressed as the ratio between the mean values in the responsive and resistant cells [Fold Of Induction (FOI)]. *p < 0.05; ***p <
0.001 treated vs. control cells. Mean values ± SD of three independent experiments.
The aim of this study was to evaluate MET efficacy also
in hypoxia, a condition that worsens cell phenotype. This
involves hypoxia-inducible factors, stem population, negative
modulation of apoptotic axis and molecular pathways
related to the regulation of cell metabolism including
PI3K/AKT/mTOR pathway.
One of the anticancer effects of MET is based on
modifications of the balance between AMPK activation and
mTOR inhibition, which leads to the negative modulation
of HIF-1α (20). Moreover, in a previous study, we showed
that a significant reduction in HIF-1α activity preceded
a response to TMZ treatment in GBM cells (18), a fact
that led us to further explore this effect also during
combined treatments.
Here, we observed that hypoxia worsened cell phenotype,
increasing HIF-1α levels, anti-apoptotic Bcl-2, and markers of
malignancy, like CD133 and CD90, this last particularly in T98.
We first studied the effect of single and combined treatment
on HIF-1α activity in GBM cells. Our results showed that
COMBO was able to reduce HIF-1α activity not only in U251-
responsive cells but also in T98 TMZ-resistant cells. Both MET
and TMZ act on AMPK (9) thus modulating HIF-1α activity and,
as shown by cell viability, COMBO administration reverted the
resistant-like pattern of T98, also in hypoxia (Figure 1). However,
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differently to what observed in U251, in T98, the increased
efficacy of COMBO in comparison to TMZ cannot be related to
the modulation of apoptotic genes.
Among other processes that can be associated to an AMPK-
dependent positive modulation of Forkhead box O3 (FOXO3)
and a negative modulation of mTOR/AKT (13), MET may
specifically act on tumor-initiating GSC cells. However, a recent
study showed that in tumors with constitutive activation of
AMPK, the anti-proliferative effect of MET on GSCs is probably
independent of AMPK (21).
Since hypoxia and HIF-1α are known to be involved in
promoting the self-renewal capacity of CD133 (22) -and CD90
positive cells, to understand the effect of MET on glioma markers
of malignancy, U251 and T98 cells were analyzed in hypoxic
condition for the expression of thesemarkers together with CD73
and CD44. Herein we demonstrated that COMBO was able to
counteract the hypoxia-induced increase of CD133, CD90, and
CD73 in TMZ-responsive cells but only that of CD90 and CD73
markers in TMZ-resistant cells, confirming the results obtained
previously in normoxia (12). However, during hypoxic condition,
the effect of COMBO was close to that of TMZ. This result
provides evidence that, during hypoxia, MET potentiates the
effect of TMZ only in U251 cells (Figure 2).
Furthermore, it has been recently discussed thatMETwas able
to block proliferation on glioma tumor-initiating cells through
the inhibition of the AKT-mTOR pathway (21). It has been
also described that AKT can be activated by TMZ and the
overexpression of its active form is positively correlated to GBM
cell resistance to TMZ. Conversely, the block of AKT-mTOR
pathway promotes TMZ responsiveness (23). AKT-mTOR block
is of particular interest in GBM since more than 40% of lesions
shows an activated pathway thanks to the loss of function or
reduced expression of the PTEN gene. Recent evidence suggested
that AMPK and AKT display antagonistic roles under metabolic
stress (24), such as in a hypoxic condition.
In addition to their mutual regulation based on specific
phosphorylation, AMPK and AKT have at least two common
targets: mTOR and FOXO. Indeed, whereas AMPK blocks mTOR
and activates FOXO, AKT is involved on the contrary process.
Thus, MET, by activating AMPK, inactivates AKT through its
dephosphorylation at Ser-473 and Thr-308 thus impairing HIF-
1α activity (24).
For these reasons, the effect of the block of AKT activation
has been herein explored by using a dual PI3K/AKT and mTOR
inhibitor, BEZ235 given alone or in combination with AMPK
modulators. The anticancer effect of this drug has been evaluated
in preclinical studies (25, 26), and recently in phase 1 clinical
trial for advanced solid tumors (colorectal, breast, non-small cell
lung carcinoma, renal, and sarcoma) (27). Dual PI3K-mTOR
inhibitors are particularly effective in blocking AKT activation
because they prevent the feedback activation of PI3K signaling
normally observed with mTORC1 inhibitors (28).
We firstly investigated the effect of BEZ235, MET, and TMZ
on hypoxia independent HIF-1α modulation when given alone
or in combination. Then, we studied the specific involvement of
the PI3K/AKT pathway by analyzing the phosphorylation form
of AKT in normoxia and hypoxia. TMZ, MET, and COMBO
reduced HIF-1α but only in U251 cells. In T98, only COMBO
was able to reduce HIF-1α although its effect was modest,
whereas TMZ administration increased its levels (Figure 4). As
expected, BEZ235 significantly reduced HIF-1α activity both
in TMZ-sensitive and -resistant cells, with a stronger effect
when combined with MET or COMBO and prevented the
increase induced by TMZ in T98 (Figures 3A,B). Partially in
line with these data, TMZ failed to reduce AKT phosphorylation
independently from cell line or condition. MET and COMBO
displayed some effects but only in TMZ responsive U251 cells.
BEZ235 given alone or in combination with MET or COMBO
displayed the highest inhibition of AKT phosphorylation.
Hypoxia-independent inhibition of HIF-1α and AKT
phosphorylation exerted by BEZ235 were not associated with
the modification of the viability of both cell lines. On the
contrary, PI3K/mTOR inhibition reduced cell viability of U251
but not that of T98 during hypoxic condition. These results
are in line with the apoptotic profile: BEZ235 was able to
reduce Bcl-2 level only during hypoxic condition and in U251
cells. This last effect is reasonability related to the block of
the hypoxia-dependent activation of AKT pathway or to a
direct effect on mTOR. Interestingly, a recent study showed
that the inhibition of hypoxia-dependent mitochondrial AKT
activation pathway was followed by an increase of cell apoptosis
and reduction of cell viability (29). This is not the case of T98
cells, where BEZ235 was not able to produce any effect on
cell viability and apoptosis also during hypoxic conditions.
Indeed, in TMZ resistant cells, reduction of cell viability was
observed only after COMBO administered alone or combined
to BEZ235 (Figure 5B). On the other hand, in this cell line,
BEZ235 associated with MET, TMZ, and particularly with
COMBO promoted a significant down-regulation of Bcl-2
anti-apoptotic gene and an up-regulation of Bax and Bad genes,
independently from oxygenation state. These results suggested
that the cooperation between the drugs could help the cells
to modulate the apoptotic switch through a double targeting
of mTOR (AMPK and PI3K/mTOR) resulting finally in the
reduction of cell viability and in the negative modulation of
HIF-1α activity.
Another potential player of MET activity is JNK/p38 MAPK,
a stress-activated kinase involved in the regulation of apoptosis
(30). Indeed, it has been recently suggested that p38 is a
direct target of MET, involved in the activation of p53 pathway
and finally in the Bax-mediated promotion of apoptosis (31).
Moreover, modulation of p38 pathway modifies the sensitivity
of cells to methylating agents, such as TMZ (32) (O6mG lesions
and their processing by the MMR system were critical for
p38α activation).
In conclusion, results obtained herein suggest that MET is
able to revert TMZ-resistance also in hypoxia, and its effect
involves the modulation of HIF-1α activity, at least in in vitro
settings. In U251 TMZ-responsive cells, the association with
MET increases the effect on markers of malignancy further
addressing the relevance of COMBO. Finally, the promotion of
a pro-apoptotic phenotype induced by BEZ235 when is added
to COMBO in T98 cells, set the basis to further investigate
in vivo, in preclinical orthotopic models, a triple therapy
Frontiers in Oncology | www.frontiersin.org 8 May 2019 | Volume 9 | Article 463
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approach based on the administration of COMBO plus double
PI3K/mTOR inhibitor.
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